Evolving Strategies for the Treatment of T-Cell Lymphoma: A Systematic Review and Recent Patents

Author(s): Kamel Laribi*, Mustapha Alani, Catherine Truong, Alix Baugier de Materre.

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 13 , Issue 3 , 2018

Submit Manuscript
Submit Proposal

Abstract:

Objective: Mature T-cell lymphomas are a heterogeneous group of T-cell malignancies with a poor outcome. The discovery of new molecular biomarkers has led to the emergence of new drugs in recent years that target various signaling pathways.

Methods: We examined all pertinent published patents through 2015 that analyzed novel methods for the diagnosis and treatment of T cell lymphoma, as well as related published and unpublished studies. Selection criteria were established before data collection. An exhaustive literature search was performed using MEDLINE and Science Direct databases. The search criteria were T-cell lymphoma, diagnosis, and treatment.

Results: Recent papers have identified recurrent epigenetic factor mutations in RHOA and FYN kinase in PTCL allowing new perspectives for epigenetic-based therapy, molecular classification model using CD28, ABCA5 transporter, coiled-coil domain-containing protein 3, and angiogenic factor SMOC2 biomarkers for differentiating forms of lymphomas, as well as expression of receptors forTNFR-1, TNFR-2, and IL12p40/70 in CTCL. New therapeutic targets have been reported such as MicroRNAs - 155 inhibitors and synthetic Toll-Like Receptor 7/8 agonists for treating CTCL, Anti CTLA-4 antibodies, anti- Killer cell immunoglobulin-like receptors 3DL2 and NK-p46 (NCR receptors) antibodies for treating PTCL, Cd1d antagonist-restricted gamma/delta-T cell lymphomas, antiEZH2, novel antihistone deacetylase, and NK cells engineered therapy.

In the transplantation setting, the objective was to eradicate overcoming of the residual disease immunity and to induce an immune tolerance by anti-third part cells with a central memory T-lymphocyte phenotype.

Conclusion: Therapeutic strategies based on a better molecular characterization of various histological types are certain to be used in the future.

Keywords: Diagnosis, drug targeting, lymphoma, methods, new agent, patents, signaling pathway, T cell.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 13
ISSUE: 3
Year: 2018
Page: [308 - 340]
Pages: 33
DOI: 10.2174/1574892813666180517102801
Price: $58

Article Metrics

PDF: 40
HTML: 1